Inventaire - your friends and communities are your best library - Inventaire

Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus.

author

John H. Beigel

published in: Antimicrobial Agents and Chemotherapy

date of publication: 2010-03-29

language: English

main subject: West Nile virus, pharmacokinetics, monoclonal antibody

Cites articles 21

Date

Title

Authors

2009-05

A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes

Michael S. Diamond, Jan Wilschut, Daved H. Fremont, Jolanda M Smit, Bastiaan Moesker
2009-04-01

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children
2008-04

West Nile virus–induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons

Michael S. Diamond, Venkatraman Siddharthan, John D Morrey, Jeffery A Hall, Jeffrey L Nordstrom, L Syd M Johnson, Ramona T Skirpstunas
2008-01-29

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products
2007-07

Defining Limits of Treatment with Humanized Neutralizing Monoclonal Antibody for West Nile Virus Neurological Infection in a Hamster Model

Michael S. Diamond, Venkatraman Siddharthan, John D Morrey, Justin G Julander, Jeffery A Hall, Jeffrey L Nordstrom, L Syd M Johnson
2006-09-22

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Michael S. Diamond, Venkatraman Siddharthan, John D Morrey, Jeffrey L Nordstrom, L Syd M Johnson
2006-09-01

West Nile virus neuroinvasive disease.

Steven A Pergam, Kenneth L. Tyler
2006-07-01

Manifestations of West Nile neuroinvasive disease

James J Sejvar, Anthony A Marfin
2005-09-29

Structural basis of West Nile virus neutralization by a therapeutic antibody
2005-05

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

Michael S. Diamond, Laura D Kramer, Gregory D Ebel, Theodore Oliphant, Daved H. Fremont, Syd Johnson, Sergey Gorlatov, Grant E Nybakken, Michael J Engle, Anantha Marri, Erin Mehlhop
2005-05-24

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers
2004-01-01

The epidemic of West Nile virus in the United States, 2002.

Brad J Biggerstaff, Susan P Montgomery, Grant L. Campbell, Anthony A Marfin
2004-08-01

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection

Xavier Sáez-Llorens
2004-06-01

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab

Ulrich Germing
2003-06-23

Human immunoglobulin as a treatment for West Nile virus infection

Lyle R. Petersen
2002-08-06

West Nile virus: a primer for the clinician
2002-09-05

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
2001-07-28

Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey

Brad J Biggerstaff
2001-08-01

Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.

Tom Wiklund
2001-06-28

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants

Lawrence Corey
2000-06-01

Trastuzumab in CSF

Article - wd:Q33876476

Welcome to Inventaire

the library of your friends and communities

you are offline